SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-24-023256
Filing Date
2024-02-29
Accepted
2024-02-29 17:10:01
Documents
100
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A apls-20231231.htm   iXBRL 10-K/A 3850918
2 EX-23.2 apls-ex23_2.htm EX-23.2 2909
3 EX-31.3 apls-ex31_3.htm EX-31.3 15299
4 EX-31.4 apls-ex31_4.htm EX-31.4 15086
5 EX-32.3 apls-ex32_3.htm EX-32.3 8429
6 EX-32.4 apls-ex32_4.htm EX-32.4 8191
7 GRAPHIC img138179509_0.jpg GRAPHIC 26034
8 GRAPHIC img138179509_1.jpg GRAPHIC 78365
9 GRAPHIC img138179509_2.jpg GRAPHIC 55504
  Complete submission text file 0000950170-24-023256.txt   14685000

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apls-20231231.xsd EX-101.SCH 2034455
102 EXTRACTED XBRL INSTANCE DOCUMENT apls-20231231_htm.xml XML 2389880
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38276 | Film No.: 24705011
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)